Among the recent studies of SGLT2 inhibitors in T2DM patients [9,10,11,12], some reported significant decreases in 3-point major adverse cardiovascular events (MACE), the occurrence of cardiovascular death [1,3] and hospitalization for HF (HHF) [9,10,11,12] in patients treated with SGLT2 inhibitors compared with the placebo-treated controls. Here, SLC5A2 is linked to hydrops fetalis.